Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Evaluating Reflexology Impact on Breast Cancer RT-Related Anxiety, Pain

October 17, 2024
By Heather Zinkin, MD
Commentary
Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.

CancerNetwork® spoke with Heather Zinkin, MD, chief of radiation medicine at Huntington Hospital of the Northwell Health Cancer Institute, about how reflexology was utilized in patients with breast cancer undergoing radiation therapy and how the efficacy of the intervention was assessed. She discussed this methodology in the context of a study she presented at the 2024 American Society of Radiation Oncology (ASTRO) Annual Meeting.

Zinkin began by highlighting the inclusion of a holistic nurse for a full workday every week, which was funded by the Northwell Center for Wellness and Integrative Medicine. She further explained that patients were offered a complimentary 15-minute session with the nurse for up to 5 weeks in a converted exam room which served as a quiet, meditative space.

Zinkin further outlined the process, whereby patients chose which portion of the body they wanted to receive reflexology, which was supplemented with mindfulness. She then stated that the impact of reflexology sessions was assessed through anonymous pre- and post-intervention stress thermometer surveys, which measured patient-reported energy, anxiety, and pain.

The study assessed 560 patient encounters from April 2022 through December 2023 to evaluate the impact of reflexology on patient-reported levels of stress, pain, and energy. Findings from the study showed that stress and pain were reduced by 40.0% and 24.0%, respectively, and that energy increased by 33.3%. Additionally, improvement in patient well-being overall was reported to have increased by 33.3% (P < .0001).

Transcript:

We were fortunately able to obtain funding from Northwell Center for Wellness and Integrative Medicine for a holistic nurse from their practice to come to our office for a full workday every week. Then we were able to offer every [patient with] breast cancer who was under treatment––receiving radiation therapy––a complimentary 15-minute session with her for up to 5 weeks. We converted one of our exam rooms into a quiet, meditative space with dim lighting, flameless candles, and some soft music. Women were able to choose what part of the body they preferred, whether it be their hands, their feet, or their neck, and they were offered 15 minutes of reflexology, including some mindfulness. Each patient was asked anonymously to complete a stress thermometer survey prior to and after each session so that we could evaluate the response to each therapy. We looked at various metrics, including energy, anxiety, and pain.

Reference

Zinkin HD, Kostroff K, Dimisa D, et al. Reflexology as an integrative approach to improve stress, energy, and pain in women receiving radiotherapy for breast cancer. Int J Radiat Oncol. 2024;120(suppl 2):e423. doi:10.1016/j.ijrobp.2024.07.944

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content

27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

Aditya Bardia, MD, MPH;Javier Cortés, MD;Francois Clement Bidard;Guillermo Streich;José García-Sáenz;Janice Lu, MD, PhD ;Giulia Tonini;Simona Scartoni;Alessandro Paoli;Alessio Fiascarelli;Alessandro Bressan;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
June 19th 2025
Article

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.

Mezigdomide Regimens Show Promise in Pretreated R/R Multiple Myeloma

Tim Cortese
June 19th 2025
Article

Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

Aditya Bardia, MD, MPH;Virginia Kaklamani, MD, DSc;Joyce A. O’Shaughnessy;Peter Schmid, MD;J. Thaddeus Beck,;Michelino De Laurentiis;Guiseppe Curigliano;Hope S. Rugo, MD;Carlos Barcenas;William J. Gradishar, MD;Michail Ignatiadis;David Cameron;Giulia Tonini;Simona Scartoni;Jennifer Crozier;Leo Viana Nicacio;Tomer Wasserman;Sara M. Tolaney, MD, MPH
June 18th 2025
Article

Findings from the phase 1b TRIMM-3 trial support the potential activity of PD-1 inhibition in patients with relapsed/refractory multiple myeloma.

Data Show Enduring Responses With Talquetamab Combo in R/R Multiple Myeloma

Gina Mauro
June 18th 2025
Article

Findings from the phase 1b TRIMM-3 trial support the potential activity of PD-1 inhibition in patients with relapsed/refractory multiple myeloma.

Related Content

27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

Aditya Bardia, MD, MPH;Javier Cortés, MD;Francois Clement Bidard;Guillermo Streich;José García-Sáenz;Janice Lu, MD, PhD ;Giulia Tonini;Simona Scartoni;Alessandro Paoli;Alessio Fiascarelli;Alessandro Bressan;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
June 19th 2025
Article

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.

Mezigdomide Regimens Show Promise in Pretreated R/R Multiple Myeloma

Tim Cortese
June 19th 2025
Article

Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

Aditya Bardia, MD, MPH;Virginia Kaklamani, MD, DSc;Joyce A. O’Shaughnessy;Peter Schmid, MD;J. Thaddeus Beck,;Michelino De Laurentiis;Guiseppe Curigliano;Hope S. Rugo, MD;Carlos Barcenas;William J. Gradishar, MD;Michail Ignatiadis;David Cameron;Giulia Tonini;Simona Scartoni;Jennifer Crozier;Leo Viana Nicacio;Tomer Wasserman;Sara M. Tolaney, MD, MPH
June 18th 2025
Article

Findings from the phase 1b TRIMM-3 trial support the potential activity of PD-1 inhibition in patients with relapsed/refractory multiple myeloma.

Data Show Enduring Responses With Talquetamab Combo in R/R Multiple Myeloma

Gina Mauro
June 18th 2025
Article

Findings from the phase 1b TRIMM-3 trial support the potential activity of PD-1 inhibition in patients with relapsed/refractory multiple myeloma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.